Employees: 950
Size Wuhan Keqian Biology (688526.SS) is a China Health Care company (Biotechnology) with a market value of $780M, the 2645th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥11.20 on 18 Nov 2026.
Performance Over six months the shares fell 23.9%, against -13.9% for the median peer and -20.0% for the China market (cap-weighted) — 7th lowest of 19 in its peer set.
Growth Revenue fell 22.2% over the last twelve months (peer median +16.0%); the operating margin is 19.9% (peer median -107.8%).
Valuation It trades at 19.4× forward earnings against a peer median of 33.9× (cheapest of 5).
Price implies For today's price to make sense, revenue must grow about 8% a year for seven years (Req g). Recent delivered growth is +2%, so the hurdle is +5 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 1.8 points below its cost of capital (9.7% WACC).
Next results Next results expected around 20 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥787M | CN¥946M | CN¥938M | CN¥1.06B | CN¥997M |
| Revenue growth | — | +1% | -11% | +6% | — |
| Gross profit | CN¥549M | CN¥613M | CN¥579M | CN¥738M | CN¥709M |
| EBITDA | n/a | CN¥480M | CN¥418M | CN¥469M | CN¥468M |
| Net income | CN¥227M | CN¥419M | CN¥382M | CN¥396M | CN¥410M |
| Free cash flow | CN¥272M | CN¥423M | CN¥326M | CN¥494M | CN¥377M |
| Capital expenditure | CN¥127M | CN¥124M | CN¥107M | CN¥105M | CN¥103M |
| Total debt | CN¥38.1M | CN¥6.68M | CN¥39.0M | CN¥327M | CN¥328M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 688526.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -7.0% | -7.1% | 11th highest of 21 |
| 6-month return | -23.9% | -13.9% | 7th lowest of 19 |
| Distance from 52-week high | -37.1% | -45.5% | 4th highest of 21 |
| Revenue growth (TTM) | -22.2% | +16.0% | 4th lowest of 16 |
| Operating margin | 19.9% | -107.8% | 3rd highest of 18 |
| Forward P/E | 19.4× | 33.9× | cheapest of 5 |
| Growth the price implies (Req g, 7 yrs) | 7.8% | 13.3% | 2nd least demanding of 5 |
| Growth delivered (Del g) | +2.4% | +7.1% | 3rd highest of 5 |
| Hurdle (Req g minus delivered) | +5.4 pp | +6.2 pp | 2nd least demanding of 5 |
| ROIC minus cost of capital | -1.8 pp | -11.1 pp | 3rd highest of 10 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Wuhan Keqian Biology 688526.SS | China | $780M | -24% | -22% | 20% | 19.4× | 7.8% | +2.4% |
| Monte Rosa Therapeutics GLUE | United States | $775M | -51% | -61% | -214% | n/a | n/a | n/a |
| Syndax Pharmaceuticals SNDX | United States | $771M | -57% | +160% | -62% | n/a | n/a | n/a |
| Nanjing Leads Biolabs 9887.HK | Hong Kong | $764M | -50% | n/a | -108% | n/a | n/a | n/a |
| Inventiva IVA.PA | France | $763M | -36% | -100% | -307,063% | n/a | n/a | n/a |
| MeiraGTx MGTX | United States | $813M | -13% | +1,366% | 44% | n/a | n/a | n/a |
| Aura Biosciences AURA | United States | $743M | -4% | n/a | n/a | n/a | n/a | n/a |
| Beijing SL Pharmaceutical 002038.SZ | China | $736M | -20% | -4% | -119% | n/a | -13.5% | -10.9% |
| Apnimed APMD | United States | $726M | n/a | +380% | -140% | n/a | n/a | n/a |
| Oxford BioMedica OXB.L | United Kingdom | $841M | -15% | +16% | -18% | n/a | n/a | n/a |
| R&G PharmaStudies 301333.SZ | China | $722M | -11% | +21% | 11% | 37.9× | 17.3% | +11.8% |
| Shaanxi Micot Pharmaceutical Technology 2335.HK | Hong Kong | $715M | n/a | n/a | n/a | n/a | n/a | n/a |
| Attovia Therapeutics ATTO | United States | $710M | +1,325% | n/a | -5,945% | n/a | n/a | n/a |
| Solid Biosciences SLDB | United States | $709M | -2% | n/a | n/a | n/a | n/a | n/a |
| Verastem VSTM | United States | $866M | +66% | +650% | -194% | n/a | n/a | n/a |
| Prime Medicine PRME | United States | $695M | +35% | +18% | -2,584% | n/a | n/a | n/a |
| Peptidream 4587.T | Japan | $878M | -3% | +14% | -18% | 29.9× | n/a | n/a |
| Anhui Wanbang Pharmaceutical Technology 301520.SZ | China | $684M | +74% | -15% | -8% | n/a | 44.8% | +14.7% |
| Kura Oncology KURA | United States | $674M | -29% | -24% | -394% | n/a | n/a | n/a |
| GNI 2160.T | Japan | $903M | -25% | +44% | -21% | 143.0× | n/a | n/a |
| Chengdu Kanghua Biological Products Co. Td Class 1 300841.SZ | China | $909M | -15% | 0% | 22% | 21.6× | 9.2% | +2.3% |